275 related articles for article (PubMed ID: 25766629)
1. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
[TBL] [Abstract][Full Text] [Related]
2. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
[TBL] [Abstract][Full Text] [Related]
3. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
[TBL] [Abstract][Full Text] [Related]
5. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
7. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
[TBL] [Abstract][Full Text] [Related]
8. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
[TBL] [Abstract][Full Text] [Related]
9. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
[TBL] [Abstract][Full Text] [Related]
10. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
[TBL] [Abstract][Full Text] [Related]
11. Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues.
Jeankumar VU; Renuka J; Kotagiri S; Saxena S; Kakan SS; Sridevi JP; Yellanki S; Kulkarni P; Yogeeswari P; Sriram D
ChemMedChem; 2014 Aug; 9(8):1850-9. PubMed ID: 24962352
[TBL] [Abstract][Full Text] [Related]
12. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
Jeankumar VU; Reshma RS; Vats R; Janupally R; Saxena S; Yogeeswari P; Sriram D
Eur J Med Chem; 2016 Oct; 122():216-231. PubMed ID: 27371925
[TBL] [Abstract][Full Text] [Related]
13. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
Sriram D; Aubry A; Yogeeswari P; Fisher LM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
[TBL] [Abstract][Full Text] [Related]
15. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
Jeankumar VU; Renuka J; Pulla VK; Soni V; Sridevi JP; Suryadevara P; Shravan M; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
Int J Antimicrob Agents; 2014 Mar; 43(3):269-78. PubMed ID: 24434114
[TBL] [Abstract][Full Text] [Related]
16. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
[TBL] [Abstract][Full Text] [Related]
17. Antimycobacterial activities of novel fluoroquinolones.
Senthilkumar P; Dinakaran M; Yogeeswari P; China A; Nagaraja V; Sriram D
Biomed Pharmacother; 2009 Jan; 63(1):27-35. PubMed ID: 18031974
[TBL] [Abstract][Full Text] [Related]
18. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
[TBL] [Abstract][Full Text] [Related]
19. Design of novel quinoline-aminopiperidine derivatives as
Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
[TBL] [Abstract][Full Text] [Related]
20. Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular hybridization from known antimycobacterial leads.
Samala G; Devi PB; Nallangi R; Sridevi JP; Saxena S; Yogeeswari P; Sriram D
Bioorg Med Chem; 2014 Mar; 22(6):1938-47. PubMed ID: 24565972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
